<pad> ACIP recommends vaccination of men who have sex with men and immunocompromised persons through age 26 years if not vaccinated previously.Why are the recommendations being updated now?9-valent HPV vaccine (9vHPV) was approved by the Food and Drug Administration on December 10, 2014. The evidence supporting 9vHPV vaccination was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework and determined to be type 2 (moderate level of evidence) among females and 3 (low level of evidence) among males; the recommendation was designated as a Category A recommendation (Recommendations for all persons in an age- or risk-factorâ€“based group).What are the new recommendations?9vHPV, 4vHPV or 2vHPV can be used for routine vaccination of females aged 11 or 12 years and females through age 26 years who have not been vaccinated previously or who have not completed the 3-dose series. ACIP recommends either 9vHPV or 4vHPV vaccination for men who have sex with men and immunocompromised persons (including those with HIV infection) through age 26 years if not vaccinated previously.<unk> M inimum intervals are 1 month between the first and second dose, 3 months between the second and</s>